Core Viewpoint - The pharmaceutical sector is experiencing a general decline, with significant drops in stock prices for various companies, attributed to seasonal factors affecting liquidity and southbound fund flows [1] Group 1: Market Performance - Major pharmaceutical stocks have seen substantial declines, with Gilead Sciences-B (01672) down 11.02% to HKD 12.92, Sanofi-B (02257) down 8.27% to HKD 8.32, and Hengrui Medicine-B (02142) down 7.29% to HKD 12.46 [1] - Overall, the Hong Kong pharmaceutical sector has performed weakly, influenced by seasonal factors such as year-end fund settlement [1] Group 2: Analyst Insights - Haitong International's report indicates that the pharmaceutical sector is under short-term pressure due to liquidity issues, but maintains a positive long-term outlook on the innovative drug industry chain [1] - The report highlights a continuous decline in the Hong Kong Stock Connect holdings of leading pharmaceutical stocks, such as Innovent Biologics and China National Pharmaceutical Group [1] Group 3: Long-term Opportunities - The firm expresses confidence in the long-term prospects of internet healthcare, CXO/research service leaders, and top biotech and pharmaceutical companies that have established external collaborations and are making progress in overseas clinical trials [1]

智通财经APP讯，和铂医药-B(02142)公布，2025年12月8日耗资约267.66万港元回购20万股股份。 ...

和铂医药-B(02142)公布，2025年12月8日耗资约267.66万港元回购20万股股份。 ...

格隆汇12月8日丨和铂医药-B(02142.HK)公告，12月8日耗资267.66万港元回购20万股，回购价格每股 12.97-13.65港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 呈交日期： 2025年12月8日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | | 是 | | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | ...

Core Insights - Multiple companies, including Tencent Holdings and China Petroleum & Chemical Corporation, conducted share buybacks on December 5, 2025, with Tencent leading in both volume and monetary value [1][2] Company Summaries - **Tencent Holdings (00700)**: Repurchased 1.046 million shares for a total of 636 million, with a year-to-date total of 85.148 million shares, representing 0.927% of total share capital [2] - **China National Offshore Oil Corporation (01919)**: Bought back 3 million shares for 41.6745 million, with a cumulative total of 6.9543 million shares, accounting for 2.415% of total share capital [2] - **Kuaishou-W (01024)**: Acquired 438,000 shares for 29.9859 million, with a year-to-date total of 682,460 shares, representing 0.159% of total share capital [2] - **Fenbi (02469)**: Conducted a buyback of 6.657 million shares for 21.0954 million, with a cumulative total of 26.657 million shares, accounting for 1.193% of total share capital [2] - **Jinxin Fertility (01951)**: Repurchased 7.722 million shares for 19.7977 million, with a total of 7.722 million shares year-to-date, representing 0.280% of total share capital [2] - **Yum China (09987)**: Engaged in two buybacks, totaling 57,000 shares for 19.1905 million, with a cumulative total of 16.2024 million shares, accounting for 4.350% of total share capital [2] - **China Feihe (06186)**: Bought back 3 million shares for 12.3 million, with a cumulative total of 208 million shares, representing 2.295% of total share capital [2] - **Haier Smart Home (06690)**: Acquired 450,000 shares for 12.1991 million, with a total of 330,000 shares year-to-date, representing 0.116% of total share capital [2] - **Vitasoy International (00345)**: Repurchased 1.302 million shares for 8.6504 million, with a cumulative total of 1.928 million shares, accounting for 1.837% of total share capital [2] - **Coolpad Group (02369)**: Conducted a buyback of 4.144 million shares for 5.5725 million, with a total of 15.048 million shares year-to-date, representing 3.925% of total share capital [2]

智通财经APP讯，和铂医药-B(02142)发布公告，于2025年12月5日，该公司斥资139.92万港元回购10万 股股份，每股回购价13.63-14.25港元。 ...

格隆汇12月5日丨和铂医药-B(02142.HK)公告，12月5日耗资140万港元回购10万股，回购价格每股13.63- 14.25港元。 ...

呈交日期： 2025年12月5日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | | 是 | | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | | 每股發行/出售價 ( ...

致：香港交易及結算所有限公司 公司名稱: 和鉑醫藥控股有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 呈交日期: 2025年12月4日 截至月份: 2025年11月30日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 20,000,000,000 | USD | | 0.000025 USD | | 500,000 | | 增加 / 減少 (-) | | | 0 | | USD | | 0 | | 本月底結存 | | 20,000,000,000 | USD | | 0.000025 USD | | 500,000 | 本月底法定/註冊股本總額： USD 500,000 第 1 頁 共 10 頁 v 1.1.1 FF ...